Are oral hypoglycemic agents likely to benefit NIDDM patients? Affirmative.
The sulfonylureas may prevent progression from impaired glucose tolerance to diabetes as well as control hyperglycemia. Patient response depends on the physiologic status of insulin secretion and effectiveness, however.